Skip to main content Back to Top

Where Do We Go from Here? Discussing the Future of Eosinophilic Esophagitis Treatment

Broadcast Date: March 25, 2022


Subscribe on iTune PodcastsListen on Google PlaySubscribe to Stitcher Podcasts Listen on Spotify Subscribe to TuneIn PodcastsSubscribe to iHeartRadio

Hear experts discuss the FDA’s recent Complete Response Letter CRL regarding Takeda’s budesonide oral solution for eosinophilic esophagitis (EoE), what therapies are in the pipeline for EoE and their potential role in therapy.


Erin Hamai TomDr. Erin Hamai Tom, PharmD, APh, MBA, BCACP is a Clinical Supervisor of Specialty Pharmacy at UC Davis Health in Sacramento, California. She earned her PharmD degree from the University of Southern California and then completed her PGY1 residency in Ambulatory Care. Dr. Hamai Tom went on to establish several pharmacist-run ambulatory care clinics for a large medical group in Southern California, focusing in primary care. She joined UC Davis Health in 2015 to launch pharmacy practices in gastroenterology and rheumatology, emphasizing specialty pharmacy medications.

Brian HemstreetDr. Brian Hemstreet, PharmD, FCCP, BCPS is currently Associate Dean and Professor at the University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences. He received both his Bachelors of Science (BS) in Pharmacy and his Doctor of Pharmacy (PharmD) degrees from The Albany College of Pharmacy in Albany, New York. He completed residencies in pharmacy practice and adult internal medicine at the Medical University of South Carolina in Charleston, South Carolina.


Relevant Financial Relationship Disclosures

No one in control of the content of this activity has a relevant financial relationship (RFR) with an ineligible company.

As defined by the Standards of Integrity and Independence in Accredited Education definition of ineligible company. All relevant financial relationships have been mitigated prior to the activity.



The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

Provided by ASHP
Supported by an independent medical education grant from Takeda Pharmaceuticals U.S.A., Inc.